Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DXX6FI
|
||||
| Drug Name |
(Z)-{2,4-Dimethyl-5-[2-oxo-6-(3-phenylureido)-1,2-dihydroindol-3-ylidene-methyl]-1H-pyrrol-3-yl}acetic acid
|
||||
| Synonyms |
CHEMBL1172422
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C24H22N4O4
|
||||
| Canonical SMILES |
Cc1[nH]c(\\C=C\\2/C(=O)Nc3cc(NC(=O)Nc4ccccc4)ccc23)c(C)c1CC(=O)O
|
||||
| InChI |
InChI=1S/C24H22N4O4/c1-13-18(12-22(29)30)14(2)25-20(13)11-19-17-9-8-16(10-21(17)28-23(19)31)27-24(32)26-15-6-4-3-5-7-15/h3-11,25H,12H2,1-2H3,(H,28,31)(H,29,30)(H2,26,27,32)/b19-11-
|
||||
| InChIKey |
LDYBJNSNFYSDIW-ODLFYWEKSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| FL cytokine receptor | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04060:Cytokine-cytokine receptor interaction | |||||
| Hematopoietic cell lineage | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Acute myeloid leukemia | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.